Send to

Choose Destination
Hepatology. 2017 Jan;65(1):65-77. doi: 10.1002/hep.28776. Epub 2016 Oct 12.

Novel plasma biomarkers associated with liver disease severity in adults with nonalcoholic fatty liver disease.

Author information

Division of Gastroenterology and, University of California-San Francisco, San Francisco, CA.
Division of Pediatric Gastroenterology, University of California-San Francisco, San Francisco, CA.
Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
Division of Pathology, University of California-San Francisco, San Francisco, CA.
Division of Gastroenterology, University of California-San Diego, San Diego, CA.
Division of Gastroenterology, Duke University, Durham, NC.
Bluestone Center for Clinical Research, New York University, New York City, NY.


Despite the high prevalence of nonalcoholic fatty liver disease (NAFLD), therapeutic options and noninvasive markers of disease activity and severity remain limited. We investigated the association between plasma biomarkers and liver histology in order to identify markers of disease activity and severity in patients with biopsy-proven NAFLD. Thirty-two plasma biomarkers chosen a priori as possible discriminators of NAFLD were measured in participants enrolled in the Nonalcoholic Steatohepatitis (NASH) Clinical Research Network. Dichotomized histologic outcomes were evaluated using centrally read biopsies. Biomarkers with statistically significant associations with NAFLD histology were evaluated in multivariable models adjusted for clinical factors. Of 648 participants (74.4% white, 61.7% female, mean age 47.7 years), 58.0% had definite NASH, 55.5% had mild/no fibrosis (stage 0-1), and 44.4% had significant fibrosis (stage 2-4). Increased activated plasminogen activator inhibitor 1 had a strong association with definite NASH compared to not NASH or borderline NASH in multivariable analysis (odds ratio = 1.20, 95% confidence interval 1.08-1.34, P < 0.001). Biomarkers associated with significant fibrosis (versus mild/no fibrosis) in multivariable analysis included higher levels of interleukin-8, monocyte chemoattractant protein-1, resistin, soluble interleukin-1 receptor I, soluble interleukin-2 receptor alpha, and tumor necrosis factor alpha and lower levels of insulin-like growth factor 2.


Specific plasma biomarkers are significantly associated with disease activity and severity of fibrosis in NAFLD and are potentially valuable tools for noninvasive stratification of patients with NAFLD and identification of targets for therapeutic intervention. (Hepatology 2017;65:65-77).

[Indexed for MEDLINE]
Free PMC Article

Conflict of interest statement

No authors report conflicts of interest/financial disclosures

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center